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ABSTRACT The effects of lysolecithin (lysophosphatidyl-
choline) derived from egg yolk as well as of synthetic lysoleci-
thins with different aliphatic chain lengths on tension devel-
opment of rabbit aortic strips were investigated. Lysolecithins
caused slowly progressing, dose-dependent relaxation that was
inhibited by hemoglobin, methylene blue, and nordihydroguia-
retic acid. Indomethacin caused no inhibition of relaxation.
The degree of relaxation was endothelium-dependent and
appeared to be related to the activation of guanylate cyclase
[GTP pyrophosphate-lyase (cyclizing), EC 4.6.1.2]. Superox-
ide dismutase failed to influence relaxation. Lysolecithins with
the longest aliphatic chain were the most potent relaxants of
aortic strips. The experiments suggest a role of lysolecithins
through their weak detergent action on membrane dynamics of
endothelial cells, resulting in the production of cyclic GMP and
the relaxation of arterial smooth muscle. Lysolecithins differ in
several respects from endothelium-derived relaxing factor.
Endothelium-derived relaxing factor is an unstable humoral
substance released from endothelium and is identical to nitric
oxide, itself a labile substance causing vascular relaxation and
cyclic GMP accumulation. Lysolecithins may represent a
different type of endothelium-dependent muscle relaxant.
Endothelial cells are involved in the regulation of regional
blood flow through production of an endothelium-derived
relaxing factor or factors (EDRF) (1). The endothelium is also
responsible for bradykinin-induced relaxation in renal and
pulmonary arteries (2). An EDRF that is distinguished from
prostanoids has been identified as nitric oxide (NO) (3, 4). In
bioassay preparation, EDRF had the same half-life, speed of
relaxation, and degree of instability as NO. In addition,
superoxide dismutase (SOD) reduced the inactivation ofboth
EDRF and NO. Like EDRF, NO effects can be inhibited by
hemoglobin (4). Evidence is now overwhelming that the
endothelium produces a factor that relaxes arterial smooth
muscle via activation of guanylate cyclase [GTP pyrophos-
phate-lyase (cyclizing), EC 4.6.1.2] with NO as mediator (5).
Lysophospholipids (lysolecithins), are formed from the
diacylphospholipids through the action of phospholipases.
Small amounts of lysolecithins are present in most mem-
branes (6). In a preliminary communication we reported that
lysolecithin, prepared by the action of phospholipase A2
(phosphatidylcholine 2-acylhydrolase, EC 3.1.1.4) from egg
yolk L-a-phosphatidylcholine, [lysolecithin (EY)] is a con-
sistent relaxant of rabbit aortic strips in the presence of
endothelium (7). Similar to lysolecithin (EY), phospholipase
A2 also produced slow dose-dependent relaxations, which
were, however, independent of the presence of endothelium
(8).
The present paper explores three related subjects: (i)
relaxation of rabbit aortic strips by lysolecithin (EY) in the
presence and absence of endothelium, (ii) the inhibitory
effect of hemoglobin, methylene blue, nordihydroguiaretic
acid (NDGA) and indomethacin on relaxation by lysolecithin
(EY), and (iii) comparisons of the degree and time of
relaxation induced by synthetic lysolecithins on intact aortic
strip and their inhibition by hemoglobin and methylene blue.
Lysolecithins were found to be potent, slow-acting vascular
smooth-muscle relaxants that activate guanylate cyclase.
Individual differences exist between different lysolecithins,
dependent on the aliphatic chain length; lysolecithin-induced
relaxation is endothelium dependent.
MATERIALS AND METHODS
Male New Zealand White rabbits weighing 2.1-3.2 kg were
anesthetized with sodium pentobarbital (30 mg/kg) and
heparinized with 500 international units/kg i.v. After trache-
otomy, the rabbits were ventilated with a respirator (Bird
Mark 10; Space Technology, Palm Springs, CA). Median
sternotomy was performed, and the thoracic portion of
descending aorta was removed and immersed immediately in
warm (370C) Krebs-Henseleit solution (9). After removal of
adjacent connective and adipose tissue, the aorta was cut into
rings of 3 mm in width, and transverse strips were
prepared. In the endothelium-denuded artery, referred to as
"rubbed preparation," endothelium was removed by the
intimal surface being gently rubbed with moistened filter
paper wrapped around a wooden stick. These strips were
mounted in an organ chamber of 20-ml capacity with both
ends fastened (9); the lower end was tied to the bottom of the
chamber, and the upper end was attached to an isometric
strain transducer (UL-20-Gr, Shinkoh, Minebea, -Tokyo).
The chambers were oxygenated with 95% 02/5% Co2 by
slow bubbling to prevent foaming. Strips were allowed to
equilibrate for 60 min, and basal (resting) tension was
adjusted to 1.5 g (8). Composition of Krebs-Henseleit solu-
tion was 143 mM Na+/5.94 mM K+/2.54 mM Ca2+/1.19
mM Mg2+/1.19 mM H2PO4 /127.84 mM Cl-/25 mM
HCO -/1.19 mM SO2-/10 mM glucose.
Tension development was induced by addition of 10' M
histamine to the organ chamber. After a steady state was
reached, 10-6 M acetylcholine was added to induce endo-
thelium-dependent relaxation, thus confirming the integrity
of endothelium.
Lysolecithins used in this series were either synthetic,
(palmitoyl, stearoyl, oleoyl, myristoyl, decanoyl, caproyl
Abbreviations: NDGA, nordihydroguiaretic acid; EDRF, endothe-
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lysolecithins) or derived from egg yolk. The latter contained
palmitoyl and stearoyl lysolecithins. The effect of lysoleci-
thin (EY) on relaxation of unrubbed intact aortic strips was
studied in 16 rabbits. After preconstriction with 10-5 M
histamine and administration of 10-6 M acetylcholine to the
bath, the preparation was washed and 10 -5 M histamine was
again applied. After steady state had been reached, cumula-
tive doses of lysolecithin (EY)-10-7 M, 10-6 M, and
10-5M-were added. The dose-response relationship of
lysolecithin was then plotted, and the time course and the
slope of relaxation was compared with that of acetylcholine.
Experiments on rubbed strips were done similarly.
Hemoglobin or methylene blue (both at concentrations of
10-5M), NDGA (3 x 10-5 M), and indomethacin (10-5 M)
were added before preconstriction with histamine. In six
experiments the inhibitory effects of hemoglobin and meth-
ylene blue were observed after relaxation with lysolecithin
when a steady state was reached. Oxyhemoglobin was
prepared, according to Martin, by adding a 10-fold molar
excess of reducing agent sodium dithionite to a 1 mM solution
of commercial bovine hemoglobin in distilled water. Sodium
dithionite was removed by dialysis against 100 vol of distilled
water for 2 hr at 40C (10).
Each synthetic lysolecithin was dissolved in 100 Al of
dimethyl sulfoxide (Me2SO) on a watch glass and diluted in
0.9 ml of Krebs-Henseleit solution. The mixture was then
stirred continuously with a glass rod until all particles had
disappeared. Final concentration of Me2SO in the organ
chamber was 0.01%; at this concentration the effect of
Me2SO on strip contractility was reported to be absent (11).
Data were expressed as mean t SEM; percent relaxation
was determined by decrease in tension from histamine-
induced contraction. The Student's t test (paired and un-
paired as indicated) was used for comparing the degree of
relaxation. All compounds were obtained from Sigma.
RESULTS
The Effect of Lysolecithin (EY) on the Relaxation of Un-
rubbed and Rubbed Aortic Strips. Fig. 1 illustrates that
lysolecithin (EY) significantly relaxed the unrubbed aortic
strip. The relaxation was dose dependent, ranging from 7.5%
with 10-7 M to 61% with 10-5 M lysolecithin (EY) (Fig. 2).
The change in tension with the highest concentration of
lysolecithin (EY) (10- M) was slightly less than that pro-
duced by 10 -6 M of acetylcholine (61% versus 68%) (Fig. 2).
Each individual decline in tension was significant as com-
pared with the preceding concentrations (P < 0.001); the
greatest decline occurred between concentrations of 10-6 to
10-5 M. Figs. 1 and 2 illustrate that relaxation in rubbed
arteries was diminished; this difference was significant at
higher concentrations of lysolecithin (EY) (10' M).
The Effect of Hemoglobin, Methylene Blue, NDGA, and
Indomethacin on the Relaxation of Lysolecithin (EY). In the
unrubbed preparations, preaddition of hemoglobin before
precontraction, significantly reduced the percent relaxation
by lysolecithin (EY), (from 61.3% to 15.2%, P < 0.001) (data
not shown). Methylene blue also inhibited relaxation from
61.3% to 4.6% (P < 0.001) (data not shown). Inhibition by
NDGA of endothelium-dependent relaxation by a variety of
relaxants were demonstrated by Chand and Altura (12).
Inhibition by NDGA was significant (from 61.3% to 37.1%),
but the difference was less (P < 0.05) (data not shown).
Indomethacin did not prevent relaxation (data not shown). In
the rubbed preparation no significant inhibition was noticed.
Furchgott et al. reported that hemoglobin administration
after relaxation by acetylcholine markedly increases tension
(13). We also observed, that when hemoglobin or methylene
blue were added to the preparation during a steady state after
relaxation with lysolecithin (EY), a marked increase in
tension was seen (Fig. 1).
The Effect of Synthetic Lysolecithins. Fig. 3 compares the
relaxing effects of synthetic stearoyl, palmitoyl, oleoyl,
myristoyl, decanoyl, and caproyl lysolecithins (10-5 M) in
the unrubbed preparation. Marked differences in the effect of
various synthetic lysolecithins were noticeable. Stearoyl,
palmitoyl, and oleoyl lysolecithins were the most active
relaxants. The decline in tension with stearoyl, palmitoyl and
oleoyl lysolecithin was 47, 37, and 36%, respectively, in
opposing the effect of histamine. No statistical differences in
the decline in tension was present between these compounds.
Lysolecithins with smaller carbon numbers influenced ten-
sion to a lesser degree (myristoyl 25%, caproyl 21%, and
decanoyl 16%) (Fig. 3). The difference between the relaxation
induced by stearoyl, on the one hand, and myristoyl, deca-
noyl and caproyl, on the other hand, was significant (P <
0.001).
Pretreatment with hemoglobin and methylene blue signif-
icantly inhibited relaxation caused by synthetic stearoyl
lysolecithin (Fig. 1).
DISCUSSION
The results illustrate that synthetic as well as lysolecithins
(EY) are potent relaxants ofvascular smooth muscle (Figs. 1-
3); the degree of relaxation depends on the presence of
endothelium (Figs. 1 and 2). Hemoglobin, methylene blue,
and NDGA inhibit relaxation, whereas indomethacin is
ineffective. It has been shown that methylene blue inhibits
cGMP (5, 14, 15) and that hemoglobin blocks the relaxation
and the increase of cGMP induced by acetylcholine (10).
When methylene blue or hemoglobin are added after relax-
ation with lysolecithins, marked contractions are recorded
(Fig. 1).
For these reasons it is likely that lysolecithins relax
vascular smooth muscle by promoting cGMP accumulation.
NDGA inhibition of the relaxing effect of a variety of
relaxants has been shown by Chand and Altura (12). Inhibi-
tion of relaxation by NDGA is less than that resulting from
methylene blue or hemoglobin, though still highly significant.
NDGA is an antioxidant and an inhibitor of lipoxygenases
and is an effective inhibitor of acetylcholine-induced relax-
ation in rabbit aortas. The inhibition by NDGA of lysoleci-
thin-induced relaxation suggests some participation of li-
poxygenases in the inhibitory process. Failure of indometh-
acin to inhibit relaxation indicates that the cyclooxygenase
pathway is not involved in the relaxation process (16, 17).
Inhibition of relaxation by hemoglobin and methylene blue
demonstrates that cGMP is the second messenger in the
relaxation of lysolecithin; a similar function of cGMP in the
relaxation by EDRF and nitrovasodilators has been repeat-
edly described (15). Previous data published from this labo-
ratory have furnished direct evidence of activation of gua-
nylate cyclase by phospholipase A2, the enzyme responsible
for the formation of lysolecithins from lecithin (8).
Relaxation induced by lysolecithin (EY) in the presence of
endothelium appears to be connected to activation of gua-
nylate cyclase. Gruetter and coworkers (18) have shown that
removal of endothelium results in a 4-fold decrease on
vascular endothelium is well known and is dependent on the
activation of guanylate cyclase by EDRF or NO (19, 20). The
link between muscarinic receptors and guanylate cyclase has
been clearly demonstrated, although vascular endothelium is
not obligatory for stimulation of cGMP formation (17). Most
probably arterial endothelial cells generate a factor that
activates guanylate cyclase.
Several significant similarities and differences exist be-
tween EDRF (NO) and lysolecithin-induced relaxation. One
of the most conspicuous is the speed of relaxation compared
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FIG. 1. Representative tracings of contractile changes of aortic strips after precontraction with histamine (HA). (A) Difference in the effect
of lysolecithin (EY) between rubbed and unrubbed aortic strips. No relaxation was noted in the rubbed preparation. (B) Dose-dependent
relaxation by lysolecithin (EY) in unrubbed aortic strip. SOD was without effect in either upper or lower traces. The addition of methylene blue
(MB) resulted in a marked increase in tension (upper trace). Similarly, hemoglobin (Hb) augmented tension particularly at higher concentrations
(10 -s M, lower trace). (C) Synthetic lysolecithin (stearoyl, 10 -5 M) caused marked relaxation (top trace). Addition of Hb and MB, added before
preconstriction with histamine, inhibited relaxation (middle and bottom traces).
with acetylcholine (ACh). In order of magnitude the percent
relaxation during the first 2 min is: ACh 63.2 + 4.8;
lysolecithin (EY) 23.8 4.1; palmitoyl 13.7 2.5; stearoyl
11.8 + 2.7; oleoyl 12.2 2.3; myristoyl 9.9 + 2.4; decanoyl
4.6 1.1; and caproyl 4.1 + 1.1.
A further important difference is the failure of SOD to
potentiate relaxation (Fig. 1). In a previous publication we
reported a small potentiating effect of SOD on lysolecithin
(EY)-produced relaxation (7). However in the present exper-
iments, the effect of SOD is either absent or negligible.
The common features between EDRF and NO and lyso-
lecithins are inhibition by hemoglobin, methylene blue, and
NDGA. Like EDRF or NO, indomethacin fails to inhibit
relaxation. It is unlikely that prostacyclins are responsible for
the relaxation induced by lysolecithins, because indometh-
acin fails to inhibit relaxation (21, 22).
Several previous publications have suggested that cleavage
of phospholipids and release of fatty acids are related to
smooth muscle relaxation. Melittin, a potent activator of
phospholipase A2 and thimerosal, which inhibits lysolecithin
acyltransferase, induce endothelium-dependent relaxations
of rabbit aortas (22, 23). Like relaxations induced by lyso-
lecithin, those resulting from thimerosal also developed more
slowly than those induced by acetylcholine (23).
In line with the concept of the phospholipid origin of
vascular smooth muscle relaxants are the results of Huang
and Lee (24) and of Bing and Saeed (7, 8). Huang and Lee
found that phospholipase A2 relaxes aortic rings (24). In
addition, relaxation by phospholipase A2 was inhibited by
methylene blue, suggesting a role of cGMP. Bing and Saeed
found that phospholipase A2 produced slow dose-dependent
relaxation in both rubbed and unrubbed precontracted aortic
strips, which is inhibited by hemoglobin and methylene blue
(8). Although in some instances slight potentiation by super-
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FIG. 2. Comparison of percent relaxation in intact (unrubbed)
and endothelium-deprived (rubbed) aortic strips. The difference in
the response to acetylcholine (ACh) was most marked (P < 0.001).
At highest (10-' M) concentrations of lysolecithin (EY) (P < 0.001)
the difference between the two preparations was also highly signif-
icant.
oxide dismutase is noticeable, this effect is inconsistent and
possibly represents an artifact.
Lysolecithins play an important role in the function of cell
membranes. Normal components of biological membranes
(1.8% of total membrane lipid in liver plasma membranes),
they are present in tissue at concentrations of "1.5 mg per ml
(25). Lysolecithins function as membrane transducers by
diffusing rapidly through the lipid portion of the membranes
to modify the activity of membrane-associated enzymes and
alter the general properties of the membrane, such as fluidity
and permeability (25). Lysolecithins are known to modify the
activity of nucleotide cyclases. For example, several workers
have recorded that soluble and insoluble guanylate cyclase
activities are stimulated by lysolecithin and phospholipase A2
(26). In addition, guanylate cyclase is stimulated by Triton
X-100 in homogenates of rat small intestine (25). Some
relationship may exist between the relaxation by surfactants
such as Triton X-100 and lysolecithins (26). We have recently
reported relaxation of aortic strips with this ionic detergent
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FIG. 3. Synthetic lysolecithins (stearoyl, oleoyl, palmitoyl, my-
ristoyl, decanoyl, or caproyl lysolecithin at i0-s M) relaxed un-
rubbed aortic strips. The degree of relaxation depended on the
aliphatic chain length. Lysolecithins with the longest aliphatic chain
showed the greatest relaxation.
(7); Fujimoto and Okabayashi found that Triton X-100,
similar to phospholipase A2, acts primarily on particulate
guanylate cyclase and that perturbation of membrane archi-
tecture, rather than solubilization, accounts for stimulation of
guanylate cyclase (27). Stimulation of guanylate cyclase
activity by fatty acid and lysolecithin (28-31) was also
described. These findings suggest a role of lysophosphatidyl-
choline in the regulation of the level of intracellular cGMP.
Fink and Gross demonstrated that amphiphiles including
palmitoyl lysophosphatidylcholine or L-palmitoyl carnitin,
were quantitatively incorporated into sarcolemma, resulting
in alterations of membrane molecular dynamics (32). These
workers, using electron-spin resonance spectroscopy dem-
onstrated that the sarcolemma contained a 4-fold higher grain
density of incorporated lysophosphatidylcholine than either
the mitochondrial or sarcoplasmic reticulum. The observed
alterations in membrane fluidity were not produced by
metabolites of amphiphilic compounds such as fatty acids or
glycerophosphorylcholine.
The relationship of the amplitude of relaxation to the
aliphatic chain length deserves some comments (Fig. 3).
Accordingly, lysolecithins with the longest chain length are
the most potent relaxants of the aortic preparation. Helenius
and coworkers (33) have related the critical micellar concen-
tration of synthetic lysolecithins to their aliphatic chain
length. Apparently the lysolecithins with shorter aliphatic
chains have higher critical micellar concentrations than those
with longer aliphatic chains. Because the critical micellar
concentrations represent the highest detergent chemical
potential attainable, it follows that those lysolecithins with
the lowest carbon number possess the highest chemical
detergent potential. Therefore, the weaker the detergent, the
greater its ability to relax aortic preparations. It must be
remembered, however, that the action of detergents on
membranes is complex, depending not only on detergent
chemical potential, but also on the nature of the detergent,
the kinetics of membrane-bound proteins, and changes in ion
flux caused by perturbation of the lipid milieu of the mem-
brane (32, 34).
In conclusion, it was found that lysolecithins are slow-
acting relaxants of rabbit aortas. They activate guanylate
cyclase, and relaxation is endothelium-dependent. Those
lysolecithins with long aliphatic chain length possess the
greatest relaxing activity, possibly related to the low degree
of detergent activity. Therefore, lysolecithins differ in many
respects from EDRF (NO) and may represent a different type
of endothelium-dependent muscle relaxant.
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